Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

05 November 2011 Study Shows Efficacy of C1-Esterase Inhibitor Concentrate in Treating Acute Attacks of Hereditary Angioedema in Children and Adolescents

New findings demonstrate that treatment with C1-esterase inhibitor (C1-INH) concentrate is effective in treating acute swelling attacks in children and adolescents with type I or type II hereditary angioedema (HAE), a rare and serious genetic disorder. Study results show that the outcomes of treatment with C1-INH during acute HAE attacks in children and adolescents are comparable to the outcomes observed in adults. Results of the analysis will be presented today at the 2011 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting.

> Read More
05 November 2011 Study Shows C1-Esterase Inhibitor Concentrate Is Safe and Consistently Effective for Long-Term Treatment of Hereditary Angioedema Attacks at Any Body Location

C1-esterase inhibitor (C1-INH) concentrate at 20 U/kg is a safe and effective therapy for the long-term treatment of successive acute swelling attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to final data presented today at the 2011 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting. Additional data presented at the meeting confirms that C1-INH concentrate provided consistent and reliable treatment response in patients treated for multiple successive HAE attacks at any body location.

> Read More
04 November 2011 National Jewish Health Names Recipient of The CSL Behring – National Jewish Health Fellowship in Immunology

National Jewish Health (NJH) announced that Jordan Abbott, M.D., is the recipient of the CSL Behring – National Jewish Health Fellowship in Immunology for 2011.

> Read More
06 October 2011 CSL Behring Named Life Sciences Company Of The Year By Philadelphia Business Journal and Pennsylvania Bio

CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies that does business in 27 countries, has been named Life Sciences Company of the Year by Philadelphia Business Journal and Pennsylvania Bio. The King of Prussia-based business is a subsidiary of CSL Limited (ASX:CSL).

> Read More
03 October 2011 Young People With Rare Medical Conditions
Faced With Care Issues and Possible
Healthcare Cuts Make Their Voices Heard

Young people between the ages of 15 and 22 converged on Washington, D.C. this summer, eager to tell elected officials their personal stories. The stories are as varied as the towns and cities from where they hail, places like San Antonio, Pittsburgh, Des Moines and New York.

> Read More
Page 26 of 50 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+